Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Differential requirements for FcγR engagement by protective antibodies against Ebola virus.

Bournazos S, DiLillo DJ, Goff AJ, Glass PJ, Ravetch JV.

Proc Natl Acad Sci U S A. 2019 Oct 1;116(40):20054-20062. doi: 10.1073/pnas.1911842116. Epub 2019 Sep 4.

PMID:
31484758
2.

Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody.

Giddens JP, Lomino JV, DiLillo DJ, Ravetch JV, Wang LX.

Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):12023-12027. doi: 10.1073/pnas.1812833115. Epub 2018 Nov 5.

3.

IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages.

Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, Sato N, DiLillo DJ, Bamford RN, Ravetch JV, Waldmann TA.

Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10915-E10924. doi: 10.1073/pnas.1811615115. Epub 2018 Oct 29.

4.

Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs.

Chen TF, Sazinsky SL, Houde D, DiLillo DJ, Bird J, Li KK, Cheng GT, Qiu H, Engen JR, Ravetch JV, Wittrup KD.

J Mol Biol. 2017 Aug 4;429(16):2528-2541. doi: 10.1016/j.jmb.2017.07.001. Epub 2017 Jul 8.

5.

Modulating IgG effector function by Fc glycan engineering.

Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX.

Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3485-3490. doi: 10.1073/pnas.1702173114. Epub 2017 Mar 13.

6.

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

DiLillo DJ, Palese P, Wilson PC, Ravetch JV.

J Clin Invest. 2016 Feb;126(2):605-10. doi: 10.1172/JCI84428. Epub 2016 Jan 5.

7.

The role of Fc-FcγR interactions in IgG-mediated microbial neutralization.

Bournazos S, DiLillo DJ, Ravetch JV.

J Exp Med. 2015 Aug 24;212(9):1361-9. doi: 10.1084/jem.20151267. Epub 2015 Aug 17. Review.

8.

Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions.

DiLillo DJ, Ravetch JV.

Cancer Immunol Res. 2015 Jul;3(7):704-13. doi: 10.1158/2326-6066.CIR-15-0120. Review.

9.

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.

DiLillo DJ, Ravetch JV.

Cell. 2015 May 21;161(5):1035-1045. doi: 10.1016/j.cell.2015.04.016. Epub 2015 May 11.

10.

humanized mice to study FcγR function.

Bournazos S, DiLillo DJ, Ravetch JV.

Curr Top Microbiol Immunol. 2014;382:237-48. doi: 10.1007/978-3-319-07911-0_11.

PMID:
25116103
11.

Type I and type II Fc receptors regulate innate and adaptive immunity.

Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV.

Nat Immunol. 2014 Aug;15(8):707-16. doi: 10.1038/ni.2939. Review.

PMID:
25045879
12.

Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice.

Lykken JM, DiLillo DJ, Weimer ET, Roser-Page S, Heise MT, Grayson JM, Weitzmann MN, Tedder TF.

J Immunol. 2014 Jul 15;193(2):746-56. doi: 10.4049/jimmunol.1302848. Epub 2014 Jun 13.

13.

Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.

DiLillo DJ, Tan GS, Palese P, Ravetch JV.

Nat Med. 2014 Feb;20(2):143-51. doi: 10.1038/nm.3443. Epub 2014 Jan 12.

14.

Regulatory B cell (B10 Cell) expansion during Listeria infection governs innate and cellular immune responses in mice.

Horikawa M, Weimer ET, DiLillo DJ, Venturi GM, Spolski R, Leonard WJ, Heise MT, Tedder TF.

J Immunol. 2013 Feb 1;190(3):1158-68. doi: 10.4049/jimmunol.1201427. Epub 2012 Dec 28.

15.

Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions.

Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Horikawa M, Kountikov EI, Spolski R, Poe JC, Leonard WJ, Tedder TF.

Nature. 2012 Nov 8;491(7423):264-8. doi: 10.1038/nature11501. Epub 2012 Oct 14.

16.

Bone marrow dendritic cell-mediated regulation of TLR and B cell receptor signaling in B cells.

Sindhava VJ, Tuna H, Gachuki BW, DiLillo DJ, Avdiushko MG, Onami TM, Tedder TF, Cohen DA, Bondada S.

J Immunol. 2012 Oct 1;189(7):3355-67. Epub 2012 Aug 31.

17.

Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.

DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y, Matsushita T, Matta KM, Chen Y, Venturi GM, Russo G, Gockerman JP, Moore JO, Diehl LF, Volkheimer AD, Friedman DR, Lanasa MC, Hall RP, Tedder TF.

Leukemia. 2013 Jan;27(1):170-82. doi: 10.1038/leu.2012.165. Epub 2012 Jul 13.

18.

Mouse model recapitulating human Fcγ receptor structural and functional diversity.

Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6181-6. doi: 10.1073/pnas.1203954109. Epub 2012 Apr 2.

19.

Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo.

Maseda D, Smith SH, DiLillo DJ, Bryant JM, Candando KM, Weaver CT, Tedder TF.

J Immunol. 2012 Feb 1;188(3):1036-48. doi: 10.4049/jimmunol.1102500. Epub 2011 Dec 23.

20.

B lymphocytes differentially influence acute and chronic allograft rejection in mice.

DiLillo DJ, Griffiths R, Seshan SV, Magro CM, Ruiz P, Coffman TM, Tedder TF.

J Immunol. 2011 Feb 15;186(4):2643-54. doi: 10.4049/jimmunol.1002983. Epub 2011 Jan 19.

21.

B-lymphocyte effector functions in health and disease.

DiLillo DJ, Horikawa M, Tedder TF.

Immunol Res. 2011 Apr;49(1-3):281-92. doi: 10.1007/s12026-010-8189-3. Review.

PMID:
21125343
22.

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF.

Blood. 2011 Jan 13;117(2):530-41. doi: 10.1182/blood-2010-07-294249. Epub 2010 Oct 20.

23.

B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.

DiLillo DJ, Yanaba K, Tedder TF.

J Immunol. 2010 Apr 1;184(7):4006-16. doi: 10.4049/jimmunol.0903009. Epub 2010 Mar 1.

24.

B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer.

DiLillo DJ, Matsushita T, Tedder TF.

Ann N Y Acad Sci. 2010 Jan;1183:38-57. doi: 10.1111/j.1749-6632.2009.05137.x. Review.

PMID:
20146707
25.

Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.

DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, Kelsoe G, Tedder TF.

J Immunol. 2008 Jan 1;180(1):361-71.

26.

Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.

DiLillo DJ, Pawluczkowycz AW, Peng W, Kennedy AD, Beum PV, Lindorfer MA, Taylor RP.

Mol Immunol. 2006 Mar;43(7):1010-9. Epub 2005 Jun 14.

PMID:
15961157
27.

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP.

J Immunol. 2004 Mar 1;172(5):3280-8.

Supplemental Content

Loading ...
Support Center